Not a healthcare professional? Visit our Public site
Not a healthcare professional? Visit our Public site
Registration successful
You now have access to the latest updates, events and resources.
Registration successful
You now have successfully registered for the event and for an account on this website.
In case you would like to receive SMS-reminders for the event you have registered, please scroll down to provide your mobile number.
Account activated – pending validation.
Your account has been activated successfully, but we still need to validate you as a healthcare professional. We’ll send you an email with the result of the validation process in the next [five] days.
In the meantime, you can enjoy access to all the latest news, events and resources on our website
Registration completed – pending validation
Your account has been activated successfully, but we still need to validate you as a Healthcare Professional registered in Ireland. We’ll send you an email with the result of the validation process. Please note this could take up to 10 days.
In the meantime, you can continue to access all the unlocked content on this website.
Account activated - pending validation.
Your account has been activated successfully, but we still need to validate you as a Healthcare Professional registered in Ireland. We’ll send you an email with the result. Please note this could take up to 10 days.
In the meantime, you can continue to access the unlocked content of the website.
Registration completed - pending validation.
Your account has been activated successfully, but we still need to validate you as a Healthcare Professional registered in Ireland. We’ll send you an email with the result of the validation process. Please note this could take up 10 days.
In the meantime, you can continue to access all the unlocked content on this website.
In case you would like to receive sms-reminders for the event you have registered, please update your communication preferences here.
Relvar: well tolerated in asthma and COPD, with over 5 million patient-years of exposure1,2
Relvar has a generally well-tolerated safety profile2 with adverse events consistent with the ICS/LABA class of medications.2
See below for a brief summary of adverse events associated with Relvar. Full details can be found in the Relvar Summary of Product Characteristics.
Very common adverse events (≥1/10)⁴ |
Common adverse events (≥1/100 to <1/10)⁴ |
|
|---|---|---|
|
|
|
Pneumonia risk in asthma4 |
Pneumonia risk in COPD4 |
|---|---|
| In an integrated analysis of 11 studies asthma (n=7034), the incidence of pneumonia per 1000 patient-years was 18.4 for Relvar 184/22 mcg vs. 9.6 for Relvar 92/22 mcg and 8.0 for placebo2 | In common with other ICS-containing medicines, there is an increased risk of pneumonia in COPD patients treated with these types of medicines. The incidence of pneumonia with Relvar is similar to that seen with other ICS/LABA combinations3 |
Footnotes
*If using on average two doses per day.
Abbreviations
COPD, chronic obstructive pulmonary disorder; ICS, inhaled corticosteroid; LABA, long-acting β2-agonist.
RELVAR Ellipta was created in collaboration with
Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.
Relvar is a registered trademark of the GlaxoSmithKline group of companies
A.G. Last updated: May 2021 PM-IE-FFV-WCNT-210007
Please update your operating system or use a different device.
